Loading…
Taizhou Jingshang Cosmetics Technology Co., Ltd., a drug manufacturer in China, was cited for significant Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter drug products. The company failed to conduct identity testing on incoming components and did not validate supplier test analyses at appropriate intervals, accepting certificates of analysis without verification. Additionally, the firm failed to adequately test incoming active pharmaceutical ingredients for required specifications. The FDA issued this warning letter after an inspection in November 2024 and noted that no response had been received from the company addressing the Form FDA 483 deficiencies.